T-Cell Gene Rearrangements and the Diagnosis of T-Cell Neoplasms

Emerging role of gammadelta T-cells in health and disease

The majority of T lymphocytes in the peripheral blood bear the alphabeta type of T-cell receptor (TCR) and less than 5% of circulating T lymphocytes bear the gammadelta type of TCR. The alphabeta and gammadelta T-cells contribute differently to the host immune defense. The immunologic function of gammadelta T-cell in humans is gradually unraveling. Pathologic studies have shown a relatively high proportion of gammadelta T-cells in the gastrointestinal mucosa, skin, and splenic red pulp where they appear to have an important immunologic function against pathogens attempting to enter body through the mucosal surfaces and possibly the skin. More data are emerging about the role of gammadelta T-cells in the course of infectious diseases and in the pathogenesis of autoimmunity. The possible role of these cells in immunologic surveillance against cancer has been inferred from their preferential expansion in certain malignancies. In parallel to the low frequency of these cells in normal lymphocytes, lymphomas bearing gammadelta type of T-cell receptors on cell surface are rare. These include hepatosplenic and non-hepatosplenic (including those involving the skin and those involving nasal cavity and upper aero digestive tract) and the rare non-B-cell cases of lymphomas seen in the immunosuppressed organ transplant patients. The limited available clinical data about gammadelta T-cell lymphomas suggest that these lymphomas tend to have an aggressive course particularly the hepatosplenic form with poor response to multi-agent chemotherapy and short median survival.

Bone marrow involvement in phenytoin induced 'pseudolymphoma'

We report a case of phenytoin induced lymph node enlargement with changes in both the lymph nodes and bone marrow suggestive of T-cell non-Hodgkin's lymphoma. The condition resolved after phenytoin withdrawal and the patient has no evidence of disease on bone marrow biopsy 15 months later.

Human autologous tumor-specific T cells in malignant melanoma

T cell lines and clones with autologous tumor-specific activity have been developed in malignant melanoma by stimulating peripheral blood lymphocytes (PBL), lymph node lymphocytes or tumor-infiltrating lymphocytes (TIL) with autologous melanoma cells in the presence of recombinant interleukin 2 (rIL2). T-cell lines and clones have been developed with specific cytotoxicity and/or proliferative responses for autologous melanoma targets but not for allogeneic melanoma tumor cells, autologous normal cells or natural killer (NK)-sensitive targets. The concentration of rIL2 is critical for the generation of autologous tumor-specific T-cell lines, with low rIL2 concentrations (up to 800 IU/ml) facilitating the growth of T-cell lines with tumor-specific activity. The alpha beta T-cell receptor (TCR) and the CD3 antigen are involved in specific cytotoxicity and/or proliferative responses of these T-cell lines and clones. An oligoclonal pattern of beta-chain TCR gene rearrangements was observed on T-cell lines and clones with autologous tumor-specific cytotoxicity, suggesting that they are comprised of T cells that have undergone a clonal expansion in response to particular antigen. Autologous tumor-specific cytotoxic T cells are HLA-restricted and recognize on the melanoma tumor cells HLA Class I or possibly Class II antigens plus a tumor-specific determinant. TIL from patients with metastatic melanoma have unique characteristics in comparison with PBL and lymph node lymphocytes and they appear to contain substantial proportions of T cells that have been locally sensitized to autologous tumor cells. Single stimulation of TIL with autologous tumor cells in the presence of rIL2 is sufficient for the generation of T cell lines with autologous tumor-specific activity, whereas, multiple stimulation of PBL and lymph node lymphocytes was required to achieve the same purpose. TIL-derived T cell lines have been expanded in rIL2 in vitro by at least 1,500-fold without losing their activity. Approximately, 40% of the patients exhibited complete or partial responses to adoptive immunotherapy with melanoma TIL and rIL2.

Lymphomatoid papulosis with antigen deletion and clonal rearrangement in a 4-year-old boy

Lymphomatoid papulosis (LyP) is rarely seen in children. We report a case of LyP in a 4-year-old boy in whom immunopathologic studies demonstrated T cell antigen deletions. In contrast to all but two previous reports, a T suppressor (CD-8) phenotype was predominant. Southern blot analysis of DNA isolated from a typical skin lesion indicated a clonal rearrangement of the T cell receptor beta gene. Because of a 10% frequency of malignant lymphomas in patients with LyP, long-term observation is crucial, especially in children. We recommend routine clonal rearrangement studies for aid in diagnosis and follow-up, and as possible prognostic indicators in children with this condition.